---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-105987"
form_type: "8-K"
ticker: null
cik: "0001260990"
company_name: "Oncternal Therapeutics, Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:10:08.431058+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Oncternal cuts 37% workforce, discontinues two clinical trials, explores strategic alternatives

## Summary
- Workforce reduction of ~10 employees (37%) to preserve cash; severance charges of ~$1.0M expected in Q3 2024.
- CMO Salim Yazji to depart effective October 1, 2024, with severance benefits.
- Discontinues ONCT-534 (prostate cancer) after interim Phase 1 showed no clinically meaningful PSA improvement in 20 patients.
- Discontinues ONCT-808 (CAR T for B-cell lymphoma); had complete metabolic response but one death at highest dose.
- Company will cease all product development and pursue strategic alternatives including sale, merger, or asset licensing.

## SEC filing metadata
- accession: 0000950170-24-105987
- form_type: 8-K
- cik: 0001260990
- company_name: Oncternal Therapeutics, Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/0000950170-24-105987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/onct-20240911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-105987
- JSON: https://secwatch.observer/filing/0000950170-24-105987.json
- Plain text: https://secwatch.observer/filing/0000950170-24-105987.txt

## Key facts
- Executive change
  Salim Yazji departed as Chief Medical Officer at Oncternal Therapeutics, Inc..
  - Action: will cease serving
  - Role: Chief Medical Officer
  source text: Salim Yazji, M.D. will cease serving as Chief Medical Officer, to be effective as of October 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/0000950170-24-105987-index.htm
- Restructurings & Charges
  Oncternal Therapeutics, Inc. announced a restructuring with charges of approximately $1.0 million (approximately 10 employees, constituting approximately 37% of Oncternal’s workforce).
  - Type: restructuring
  - Charge: approximately $1.0 million
  - Headcount: approximately 10 employees, constituting approximately 37% of Oncternal’s workforce
  source text: Oncternal currently estimates that it will incur charges associated with the workforce reduction of approximately $1.0 million primarily related to employee severance payments, benefits and related termination costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/0000950170-24-105987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.